Up­dat­ed: Ar­bi­tra­tor awards $157M to Soon-Sh­iong's Im­mu­ni­ty­Bio in dis­pute with Sor­ren­to

Sor­ren­to Ther­a­peu­tics’ years­long bat­tle with Nant­Cell and NAN­Ti­body has come to an ar­bi­tra­tion award, but ad­di­tion­al le­gal pro­ceed­ings cen­tered around a “catch-and-kill” scheme re­main pend­ing.

On Fri­day, the ar­bi­tra­tor in the dis­pute be­tween Sor­ren­to and Nant­Cell and Im­munother­a­py NAN­Ti­body LLC is­sued an award that grants con­trac­tu­al dam­ages and pre-award in­ter­est.

The ar­bi­tra­tor award­ed Nant­Cell (part of bil­lion­aire Patrick Soon-Sh­iong’s Im­mu­ni­ty­Bio) near­ly $157 mil­lion and NAN­Ti­body close to $17 mil­lion. Post-award, pre­judg­ment in­ter­est will ac­crue at 9% per an­num, ac­cord­ing to an SEC fil­ing sent in by Sor­ren­to.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER